Literature DB >> 32946567

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib.

Paul J Hampel1, Hua-Jay J Cherng2, Timothy G Call1, Wei Ding1, Mahsa Khanlari3, Ellen D McPhail4, Roberto N Miranda3, Pei Lin3, Hussein A Tawbi5, Alessandra Ferrajoli2, William G Wierda2, Nitin Jain2, Sameer A Parikh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32946567      PMCID： PMC7509865          DOI： 10.1182/bloodadvances.2020002454

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  16 in total

1.  Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL.

Authors:  Inhye E Ahn; Neil Basumallik; Xin Tian; Susan Soto; Adrian Wiestner
Journal:  Blood       Date:  2019-03-27       Impact factor: 22.113

2.  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillermo Dighiero; Hartmut Döhner; Peter Hillmen; Michael Keating; Emili Montserrat; Nicholas Chiorazzi; Stephan Stilgenbauer; Kanti R Rai; John C Byrd; Barbara Eichhorst; Susan O'Brien; Tadeusz Robak; John F Seymour; Thomas J Kipps
Journal:  Blood       Date:  2018-03-14       Impact factor: 22.113

3.  Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome.

Authors:  Ekaterina Chigrinova; Andrea Rinaldi; Ivo Kwee; Davide Rossi; Paola M V Rancoita; Jonathan C Strefford; David Oscier; Kostas Stamatopoulos; Theodora Papadaki; Francoise Berger; Ken H Young; Fiona Murray; Richard Rosenquist; Timothy C Greiner; Wing C Chan; Ester M Orlandi; Marco Lucioni; Roberto Marasca; Giorgio Inghirami; Marco Ladetto; Francesco Forconi; Sergio Cogliatti; Hana Votavova; Steven H Swerdlow; Stephan Stilgenbauer; Miguel A Piris; Andras Matolcsy; Dominic Spagnolo; Eugene Nikitin; Alberto Zamò; Valter Gattei; Govind Bhagat; German Ott; Emanuele Zucca; Gianluca Gaidano; Francesco Bertoni
Journal:  Blood       Date:  2013-09-04       Impact factor: 22.113

4.  Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.

Authors:  Paul M Barr; Jennifer R Brown; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Stephen P Mulligan; Ulrich Jaeger; Richard R Furman; Florence Cymbalista; Marco Montillo; Claire Dearden; Tadeusz Robak; Carol Moreno; John M Pagel; Jan A Burger; Samuel Suzuki; Juthamas Sukbuntherng; George Cole; Danelle F James; John C Byrd
Journal:  Blood       Date:  2017-04-03       Impact factor: 22.113

5.  Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.

Authors:  Preetesh Jain; Philip A Thompson; Michael Keating; Zeev Estrov; Alessandra Ferrajoli; Nitin Jain; Hagop Kantarjian; Jan A Burger; Susan O'Brien; William G Wierda
Journal:  Cancer       Date:  2017-02-07       Impact factor: 6.860

6.  Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Authors:  Paul J Hampel; Wei Ding; Timothy G Call; Kari G Rabe; Saad S Kenderian; Thomas E Witzig; Eli Muchtar; Jose F Leis; Asher A Chanan-Khan; Amber B Koehler; Amie L Fonder; Susan M Schwager; Susan L Slager; Tait D Shanafelt; Neil E Kay; Sameer A Parikh
Journal:  Leuk Lymphoma       Date:  2019-04-24

7.  Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.

Authors:  A R Mato; B T Hill; N Lamanna; P M Barr; C S Ujjani; D M Brander; C Howlett; A P Skarbnik; B D Cheson; C S Zent; J J Pu; P Kiselev; K Foon; J Lenhart; S Henick Bachow; A M Winter; A-L Cruz; D F Claxton; A Goy; C Daniel; K Isaac; K H Kennard; C Timlin; M Fanning; L Gashonia; M Yacur; J Svoboda; S J Schuster; C Nabhan
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

8.  Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.

Authors: 
Journal:  Haematologica       Date:  2016-10-18       Impact factor: 9.941

9.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

10.  Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.

Authors:  Yucai Wang; Marcella A Tschautscher; Kari G Rabe; Timothy G Call; Jose F Leis; Saad S Kenderian; Neil E Kay; Eli Muchtar; Daniel L Van Dyke; Amber B Koehler; Susan M Schwager; Susan L Slager; Sameer A Parikh; Wei Ding
Journal:  Haematologica       Date:  2019-06-13       Impact factor: 9.941
View more
  3 in total

Review 1.  Biology and Treatment of Richter Transformation.

Authors:  Adalgisa Condoluci; Davide Rossi
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

2.  An Approach to Diagnosis of Richter Transformation in Chronic Lymphocytic Leukemia.

Authors:  Jackie Broadway-Duren
Journal:  J Adv Pract Oncol       Date:  2022-07-27

3.  Life-Threatening Fungal Infection in Richter Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Case Report and Brief Review of Literature.

Authors:  Binav Baral; Kriti Ahuja; Navika Chhabra; Muhammad J Tariq; Maryam Zia
Journal:  Cureus       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.